Manoj Rao, MD
Urology · Merrillville, INNPI 1790946168
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,083 of the $35,590 with a category attached, or 70.5%. 57 manufacturers reported payments, led by Myriad Genetic Laboratories, Inc. at 45.2% of the total. Reporting peaked in 2021 at $15,950 and has fallen 78.7% since, to $3,403 in 2025. Among urology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 331 payments — averaging $107.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$16K
- Merck$5K
- Janssen Scientific Affairs, LLC$4K
- Neotract Inc.$2K
- Johnson & Johnson$2K
- Pfizer$2K
- plus $6K from 51 others
Across 45 payments — averaging $7356.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$287K
- Dendreon Pharmaceuticals LLC$27K
- Janssen Research & Development, LLC$17K
What the payments were for
- Consulting fees$25,08370%
- Speaking & faculty fees$3251%
- Travel & lodging$2,6477%
- Food & beverage$7,27120%
- Education$2651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRACAnalysis CDx$10,921
- myRisk$4,099
- UroLift$1,907
- AKEEGA$818
- TITAN$331
- Prolaris$283
- BIOPROTECT BALLOON IMPLANT SYSTEM$179
- CVAC Aspiration System$156
- JELMYTO$143
- Monarch Platform$131
- PROVENGE$127
- GENERAL ERECTILE DYSFUNCTION$113
- Cysview$107
- N/A$102
How this compares
$35,590 in reported general payments places this provider in the 90th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 111 | $292,519 |
| MyrbetriqMirabegron | 75 | $55,391 |
| Tamsulosin Hcl | 819 | $10,479 |
| Tolterodine Tartrate ErTolterodine Tartrate | 61 | $5,446 |
| Finasteride | 374 | $3,857 |
| Oxybutynin Chloride ErOxybutynin Chloride | 139 | $2,619 |
| Dutasteride | 24 | $1,269 |
| NitrofurantoinNitrofurantoin Macrocrystal | 36 | $1,241 |
| Tolterodine Tartrate | 12 | $1,177 |
| Estradiol | 22 | $1,038 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 17 | $725 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 108 | $716 |
| Solifenacin Succinate | 15 | $493 |
| Oxybutynin Chloride | 32 | $472 |
| Cephalexin | 109 | $449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $303 | $292,519111 claims |
| Astellas Pharma US IncMyrbetriq | $425 | $55,39175 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 272 urology providers in Indiana.
Other urology in Merrillville
- Ayoola GomihMerrillville$20K
- Bruce YalowitzMerrillville$11K
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Matthew MellonCarmel$159K
- James BailenJeffersonville$143K
- Greg SteinbockJeffersonville$134K
- Eugene ConeGreenwood$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.